Eleanor N Fish

List of Publications by Year
in descending order

75 papers	5,482 citations	117625 34 h-index	85541 71 g-index
80 all docs	80 docs citations	80 times ranked	10263 citing authors

#	Article	IF	Citations
1	The X-files in immunity: sex-based differences predispose immune responses. Nature Reviews Immunology, 2008, 8, 737-744.	22.7	883
2	Sex-based differences in immune function and responses to vaccination. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 9-15.	1.8	425
3	Interferon Alfacon-1 Plus Corticosteroids in Severe Acute Respiratory Syndrome. JAMA - Journal of the American Medical Association, 2003, 290, 3222.	7.4	360
4	Sex affects immunity. Journal of Autoimmunity, 2012, 38, J282-J291.	6.5	339
5	Interferon-Î±2b Treatment for COVID-19. Frontiers in Immunology, 2020, 11, 1061.	4.8	314
6	Chemokines: attractive mediators of the immune response. Seminars in Immunology, 2003, 15, 5-14.	5.6	235
7	Activation of the p38 Mitogen-activated Protein Kinase by Type I Interferons. Journal of Biological Chemistry, 1999, 274, 30127-30131.	3.4	211
8	Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4808-4813.	7.1	183
9	Review: IFN-Î±/Î²Receptor Interactions to Biologic Outcomes: Understanding the Circuitry. Journal of Interferon and Cytokine Research, 2002, 22, 835-845.	1.2	174
10	Influenza Virus Non-Structural Protein 1 (NS1) Disrupts Interferon Signaling. PLoS ONE, 2010, 5, e13927.	2.5	140
11	Contribution of Interferon-Î² to the Murine Macrophage Response to the Toll-like Receptor 4 Agonist, Lipopolysaccharide. Journal of Biological Chemistry, 2006, 281, 31119-31130.	3.4	139
12	Global virus outbreaks: Interferons as 1st responders. Seminars in Immunology, 2019, 43, 101300.	5.6	113
13	RANTES Activates Jak2 and Jak3 to Regulate Engagement of Multiple Signaling Pathways in T Cells. Journal of Biological Chemistry, 2001, 276, 11427-11431.	3.4	98
14	The yin and yang of viruses and interferons. Trends in Immunology, 2012, 33, 190-197.	6.8	98
15	Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways. Frontiers in Immunology, 2020, 11, 606456.	4.8	98
16	CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1. Blood, 2008, 111, 4892-4901.	1.4	84
17	Interferon Receptor Signaling in Malignancy: A Network of Cellular Pathways Defining Biological Outcomes. Molecular Cancer Research, 2014, 12, 1691-1703.	3.4	77
18	CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochemical and Biophysical Research Communications, 2009, 387, 381-386.	2.1	69

#	Article	IF	Citations
19	Central Role of ULK1 in Type I Interferon Signaling. Cell Reports, 2015, 11, 605-617.	6.4	66
20	Critical roles for IFN-Â in lymphoid development, myelopoiesis, and tumor development: Links to tumor necrosis factor Â. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 13453-13458.	7.1	65
21	The Chemokine CCL5 Regulates Glucose Uptake and AMP Kinase Signaling in Activated T Cells to Facilitate Chemotaxis. Journal of Biological Chemistry, 2012, 287, 29406-29416.	3.4	63
22	CCL5-CCR5-mediated Apoptosis in T Cells. Journal of Biological Chemistry, 2006, 281, 25184-25194.	3.4	61
23	Fibrocyte activation in rheumatoid arthritis. Rheumatology, 2010, 49, 640-651.	1.9	57
24	The Interferon-Inducible Stat2:Stat1 Heterodimer Preferentially BindsIn Vitroto a Consensus Element Found in the Promoters of a Subset of Interferon-Stimulated Genes. Journal of Interferon and Cytokine Research, 2001, 21, 379-388.	1.2	55
25	CCL5 activation of CCR5 regulates cell metabolism to enhance proliferation of breast cancer cells. Open Biology, 2016, 6, 160122.	3.6	51
26	The role of circulating fibrocytes in inflammation and autoimmunity. Journal of Leukocyte Biology, 2013, 93, 45-50.	3.3	48
27	A Rapid Screening Assay Identifies Monotherapy with Interferon-ÃŸ and Combination Therapies with Nucleoside Analogs as Effective Inhibitors of Ebola Virus. PLoS Neglected Tropical Diseases, 2016, 10, e0004364.	3.0	48
28	Interferon Î²-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. PLoS ONE, 2017, 12, e0169255.	2.5	48
29	Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7723-7728.	7.1	46
30	Circulating fibrocytes contribute to the pathogenesis of collagen antibodyâ€“induced arthritis. Arthritis and Rheumatism, 2012, 64, 3583-3593.	6.7	42
31	Multiparameter Phospho-Flow Analysis of Lymphocytes in Early Rheumatoid Arthritis: Implications for Diagnosis and Monitoring Drug Therapy. PLoS ONE, 2009, 4, e6703.	2.5	41
32	Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by interferon-Î². Blood, 2009, 114, 2623-2631.	1.4	37
33	A structural basis for interferonâ€Î±â€receptor interactions. FASEB Journal, 2007, 21, 3288-3296.	0.5	36
34	Engagement of the CrkL adaptor in interferon Î± signalling in BCR-ABL-expressing cells. British Journal of Haematology, 2001, 112, 327-336.	2.5	35
35	CCL5-CCR5 interactions modulate metabolic events during tumor onset to promote tumorigenesis. BMC Cancer, 2017, 17, 834.	2.6	34
36	Distinct Signature Type I Interferon Responses are Determined by the Infecting virus and the Target Cell. Antiviral Therapy, 2008, 13, 409-422.	1.0	31

#	Article	IF	Citations
37	Identification of a novel antigen-presenting cell population modulating antiinfluenza type 2 immunity. Journal of Experimental Medicine, 2010, 207, 1435-1451.	8.5	30
38	Interferon-Î±2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities. Viruses, 2021, 13, 44.	3.3	29
39	Cutting Edge: Endogenous IFN-Î² Regulates Survival and Development of Transitional B Cells. Journal of Immunology, 2017, 199, 2618-2623.	0.8	28
40	Interferon-Î² modulates type 1 immunity during influenza virus infection. Antiviral Research, 2010, 88, 64-71.	4.1	26
41	LAPCs promote follicular helper T cell differentiation of Ag-primed CD4+ T cells during respiratory virus infection. Journal of Experimental Medicine, 2012, 209, 1853-1867.	8.5	26
42	Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Blood, 2019, 133, 1171-1185.	1.4	26
43	Interferon Î³ (IFNÎ³) Signaling via Mechanistic Target of Rapamycin Complex 2 (mTORC2) and Regulatory Effects in the Generation of Type II Interferon Biological Responses. Journal of Biological Chemistry, 2016, 291, 2389-2396.	3.4	25
44	Fibrocyte and T cell interactions promote disease pathogenesis in rheumatoid arthritis. Journal of Autoimmunity, 2016, 69, 38-50.	6.5	24
45	Sirtuin 2â€“mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses. Journal of Biological Chemistry, 2019, 294, 827-837.	3.4	24
46	Changing oral vaccine to inactivated polio vaccine might increase mortality. Lancet, The, 2016, 387, 1054-1055.	13.7	21
47	Chemokines in breast cancer: Regulating metabolism. Cytokine, 2018, 109, 57-64.	3.2	21
48	Critical Roles for Rictor/Sin1 Complexes in Interferon-dependent Gene Transcription and Generation of Antiproliferative Responses. Journal of Biological Chemistry, 2014, 289, 6581-6591.	3.4	19
49	Interferonâ€Î² regulates dendritic cell activation and migration in experimental autoimmune encephalomyelitis. Immunology, 2017, 152, 439-450.	4.4	18
50	IFN-Î³â€“inducible antiviral responses require ULK1-mediated activation of MLK3 and ERK5. Science Signaling, 2018, 11, .	3.6	17
51	Interleukin-34 Promotes Fibrocyte Proliferation. Journal of Interferon and Cytokine Research, 2017, 37, 440-448.	1.2	15
52	Chemokines and Cancer. , 2005, 126, 15-44.		14
53	Slfn2 Regulates Type I Interferon Responses by Modulating the NF-Î¤B Pathway. Molecular and Cellular Biology, 2018, 38, .	2.3	13
54	Regulatory effects of SKAR in interferon Î± signaling and its role in the generation of type I IFN responses. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11377-11382.	7.1	11

#	Article	IF	Citations
55	De Novo Design of Nonpeptidic Compounds Targeting the Interactions between Interferon-Î± and its Cognate Cell Surface Receptor. Journal of Medicinal Chemistry, 2008, 51, 2734-2743.	6.4	10
56	Immunoregulatory Effects of Interferon-Î² in Suppression of Th17 cells. Journal of Interferon and Cytokine Research, 2014, 34, 330-341.	1.2	10
57	Schlafen 5 as a novel therapeutic target in pancreatic ductal adenocarcinoma. Oncogene, 2021, 40, 3273-3286.	5.9	8
58	Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms. Nature Communications, 2022, 13, 1750.	12.8	8
59	WFDC1/ps20: A host factor that influences the neutrophil response to murine hepatitis virus (MHV) 1 infection. Antiviral Research, 2012, 96, 158-168.	4.1	7
60	Residues F103 and M106 within the influenza A virus NS1 CPSF4-binding region regulate interferon-stimulated gene translation initiation. Virology, 2017, 508, 170-179.	2.4	7
61	A Conserved Residue, Tyrosine (Y) 84, in H5N1 Influenza A Virus NS1 Regulates IFN Signaling Responses to Enhance Viral Infection. Viruses, 2017, 9, 107.	3.3	7
62	Central Regulatory Role for SIN1 in Interferon Î³ (IFNÎ³) Signaling and Generation of Biological Responses. Journal of Biological Chemistry, 2017, 292, 4743-4752.	3.4	6
63	Interactions Between NS1 of Influenza A Viruses and Interferon-Î±/Î²: Determinants for Vaccine Development. Journal of Interferon and Cytokine Research, 2017, 37, 331-341.	1.2	6
64	Plasma Proteomic Analysis Distinguishes Severity Outcomes of Human Ebola Virus Disease. MBio, 2022, 13, e0056722.	4.1	5
65	Small molecule mimetics of an interferon-Î± receptor interacting domain. Bioorganic and Medicinal Chemistry, 2014, 22, 978-985.	3.0	4
66	Sex Differences in the Immune Response. , 2015, , 1-29.		4
67	A cluster randomized trial of interferon ÃŸ-1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19). BMC Infectious Diseases, 2021, 21, 814.	2.9	4
68	Small Molecule Agonists for the Type I Interferon Receptor: An In Silico Approach. Journal of Interferon and Cytokine Research, 2016, 36, 180-191.	1.2	3
69	A combination treatment of IFN-Î±2b and IFN-Î³ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trial. Annals of Antivirals and Antiretrovirals, 2021, , 001-014.	0.5	2
70	Regulation of IFNÎ±-induced expression of the short ACE2 isoform by ULK1. Molecular Immunology, 2022, 147, 1-9.	2.2	1
71	Introduction to special issue on interferons. Seminars in Immunology, 2019, 43, 101327.	5.6	0
72	Amanda E. I. Proudfoot 1949â€“2019. Nature Immunology, 2020, 21, 241-241.	14.5	0

#	Article	IF	Citations
73	Activated Fibrocytes in Rheumatoid Arthritis. , 2011, , 253-270.		0
74	Introduction. Vaccine, 2022, 40, 1513-1515.	3.8	0
75	Tribute to Howard Young. Journal of Interferon and Cytokine Research, 2022, , .	1.2	0